Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net loss	$ (65,175)	$ (35,874)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	49	42
Stock-based compensation expense	7,292	4,511
Amortization of premiums and accretion of discounts on marketable securities, net	(4,599)	(1,344)
Change in fair value of embedded derivatives	(1,040)	0
Amortization of right-of-use asset	85	103
Realized gains on marketable securities	(97)	0
Non-cash interest expense	823	0
Other non-cash expense	230	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(4,196)	(436)
Other assets	51	(38)
Accounts payable	963	(278)
Accrued clinical trial expenses	8,130	(1,151)
Accrued expenses and other current liabilities	(1,413)	(182)
Finance lease liability	(23)	0
Operating lease liability	(80)	(103)
Net cash used in operating activities	(59,000)	(34,750)
Cash flows from investing activities
Purchases of marketable securities	(155,631)	(178,857)
Proceeds from maturities and sales of marketable securities	174,011	55,997
Proceeds from sale of property and equipment	0	3
Purchases of property and equipment	(16)	(7)
Net cash provided by (used in) investing activities	18,364	(122,864)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	7,938	122,294
Payment for financing lease	(739)	0
Payments for deferred offering costs	(230)	0
Repurchase of common shares to pay employee withholding taxes	(32)	0
Proceeds from exercise of stock options	0	325
Net cash provided by financing activities	6,937	122,619
Net change in cash and cash equivalents and restricted cash	(33,699)	(34,995)
Cash and cash equivalents and restricted cash at the beginning of the period	67,119	130,101
Cash and cash equivalents and restricted cash at the end of the period	33,420	95,106
Supplemental disclosure of cash flow information
Cash paid for income taxes	0	0
Cash paid for interest	2,235	0
Supplemental disclosure of noncash investing and financing activities
Proceeds from sale of property and equipment in other current assets	$ 0	$ 4